As PRA mulls an IPO, three private equity heavyweights are reportedly looking to bid on the CRO, and current owner Genstar Capital could well be pushing talk of going public just to tick up the asking price.
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.
ICU Medical's bid to sell itself kicks into its next round this week, with the California device maker expected to seek second-round bids. As Reuters reports, a few interested parties have already emerged, including larger rival CareFusion, Hospira and at least one private equity firm.
Elan and Royalty Pharma have been in a rapid back and forth of one-upmanship to win the hearts and votes of Elan shareholders. But the latest offer from Royalty may turn the the tide.
Seaside Therapeutics has suffered a string of setbacks recently. Swiss drug giant Roche has passed on taking an option on Cambridge, MA-based Seaside's lead drug candidate arbaclofen, which the biotech startup revealed last month flunked a Phase II autism study and Phase III trial in Fragile X patients.
Royalty has sought to win over investors with an offer of $13 per share and a $2.50 CVR, a jump from the previous $12.50 per share offer that the vast majority of Elan shareholders rebuffed.
Bayer has wrapped up its $1.1 billion acquisition of Conceptus, adding the company's permanent birth control device to its flagging contraceptive business.
Medical device maker Teleflex is snatching up a promising Israeli startup focused on minimally invasive microlaparoscopy surgical technology.
Thermo Fisher is selling off $2.2 billion of its common stock, looking to raise funds to help close out its $13.6 billion buyout of Life Technologies.
A year after Johnson & Johnson snatched up Swiss orthopedic devicemaker Synthes for an astounding $21.3 billion, the merging of operations is incredibly slow-going and has cost the combined company some business and research talent, the Swiss publication Finanz und Wirtschaft ( Finance and Economics ) reports.